BioSpace News Archive

Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, completed the expansion of its global manufacturing and distribution facilities in Roswell, Georgia.

Pharvaris recently presented data highlighting the unique pharmacological and clinical properties of deucrictibant for the treatment and prevention of HAE attacks at the 20th Annual Congress of International Drug Discovery Science and Technology ; the 2024 Eastern Allergy Conference ; and the European Academy of Allergy and Clinical Immunology Congress 2024.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 74,875 shares, and restricted stock units covering an aggregate of 39,050 shares, of BioCryst common stock.

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announces the launch of the Catalyst® Pancreatic Lipase Test, a single-slide solution for canine and feline patients suspected of pancreatitis.

Viking Therapeutics, Inc. today announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).

First-in-human PET imaging study of 64Cu-PD-32766 for patients with clear cell renal cell carcinoma were initiated.

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced comprehensive results from the company’s pivotal Phase 3 study of uproleselan in R/R AML.

Amarin Corporation plc today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO).

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Truist Securities Medtech Conference on Tuesday, June 18, 2024.

iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Digital Healthcare Conference on June 11-12, 2024 in San Francisco, CA.